Early detection improves treatment outcomes for endometrial and ovarian cancers, yet far too often women are diagnosed in advanced stages of these diseases. Unlike many other cancers, there… read more.
GSK plc announced statistically significant and clinically meaningful overall survival (OS) results from Part 1 and progression-free survival (PFS) results from Part 2 of the RUBY/ENGOTEN6/GOG3031/NSGO phase III… read more.
Merck Inc., known as MSD outside of the United States and Canada, and Eisai announced that the Phase III LEAP-001 trial evaluating Keytruda, Merck’s anti-PD-1 therapy, plus Lenvima,… read more.
The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised a new indication for Jemperli (dostarlimab), a treatment for some types of endometrial cancer in adults. It can… read more.
GSK plc announced that the FDA has approved Jemperli (dostarlimab) in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult… read more.
Researchers from a phase 2 study report that combination treatment with abemaciclib and letrozole shrinks or stabilizes tumors in a majority of subjects diagnosed with recurrent or persistent… read more.
Eisai Co., Ltd. and Merck Inc., announced that the European Commission has approved the combination of Lenvima, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai,… read more.
The FDA has approved pembrolizumab (Keytruda) in combination with lenvatinib (Lenvima) for patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR),… read more.
Merck Inc and Eisai announced that the FDA has accepted and granted priority review for an application seeking new approval for the combination of Keytruda (pembrolizumab) plus Lenvima… read more.
There is no excerpt because this is a protected post.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
